LILAC Study For Patients with Cutaneous and/or Systemic Lupus

  • STATUS
    Recruiting
Updated on 25 March 2021

Summary

LILAC Study For Patients with Cutaneous and/or Systemic Lupus

Description

If you or a family member have cutaneous lupus erythematosus (CLE) and/or systemic lupus erythematosus (SLE), you may want to consider the LILAC clinical research study.

What is the purpose of the LILAC study?

The purpose of the LILAC study is to learn if an investigational medication may effectively reduce lupus skin activity in patients with CLE and/or SLE.

What is the investigational medication?

The investigational medication, BIIB059, is a monoclonal antibody administered as a subcutaneous injection. Antibodies are designed to recognize and attach to specific molecules in your body. BIIB059 attaches to the surface of a specific type of cell that is part of the immune system. When BIIB059 attaches to the immune system cells, it limits the production of certain protein, called IFNa, which may be associated with CLE and SLE symptoms.

Who can participate in the LILAC study?

You may be able to participate in this study if you:
  • Are 18 to 75 years old
  • Have been diagnosed with CLE and/or SLE
  • Have active lupus skin disease

How long is the study?

If you are eligible for the study, your participation may last 28 to 40 weeks and include up to 13 visits to the study site.

Details
Condition Subacute cutaneous lupus erythematosus
Clinical Study IdentifierTX12503
Last Modified on25 March 2021

Eligibility

How to participate?

Step 1 Connect with a site
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar
Name

Primary Contact

site
Name

0/250
Preferred Language
Other Language
Please verify that you are not a bot.

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Loading...

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note